These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36343572)

  • 1. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
    Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
    EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
    Dobard CW; Peet MM; Nishiura K; Holder A; Dinh C; Mitchell J; Khalil G; Pan Y; Singh ON; McCormick TJ; Agrahari V; Gupta P; Jonnalagadda S; Heneine W; Clark MR; García-Lerma JG; Doncel GF
    EBioMedicine; 2022 Dec; 86():104361. PubMed ID: 36423375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
    Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
    Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
    Riddler SA; Kelly CW; Hoesley CJ; Ho KS; Piper JM; Edick S; Heard F; Doncel GF; Johnson S; Anderson PL; Brand RM; Kunjara Na Ayudhya RP; Bauermeister JA; Hillier SL; Hendrix CW
    J Infect Dis; 2024 Sep; 230(3):696-705. PubMed ID: 38655842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention.
    Peet MM; Agrahari V; Clark MR; Doncel GF
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques.
    Makarova N; Singletary T; Peet MM; Mitchell J; Bachman S; Holder A; Dinh C; Lipscomb J; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Doncel GF; Smith JM
    J Infect Dis; 2024 Jun; 229(6):1791-1795. PubMed ID: 38134382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
    Massud I; Ruone S; Zlotorzynska M; Haaland R; Mills P; Cong ME; Kelley K; Johnson R; Holder A; Dinh C; Khalil G; Pan Y; Kelley CF; Sanchez T; Heneine W; García-Lerma JG
    EBioMedicine; 2020 Aug; 58():102894. PubMed ID: 32707451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
    Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
    Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.
    Massud I; Nishiura K; Ruone S; Holder A; Dinh C; Lipscomb J; Mitchell J; Khalil GM; Heneine W; Garcia-Lerma JG; Dobard CW
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
    J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention.
    Jhunjhunwala K; Dobard CW; Sharma S; Makarova N; Holder A; Dinh C; Mitchell J; Wang L; Zhang J; Patel SK; Heneine W; Rohan LC
    Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
    Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
    Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
    Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
    EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
    Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
    EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
    Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
    Radzio J; Aung W; Holder A; Martin A; Sweeney E; Mitchell J; Bachman S; Pau CP; Heneine W; García-Lerma JG
    PLoS One; 2012; 7(12):e50632. PubMed ID: 23226529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A; Podzamczer D
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.